Want to see XFOR full AI Analyst Report?
XFOR Stock Chart & Stats
$4.17
$0.09(2.34%)
At close: 4:00 PM EDT
$4.17
$0.09(2.34%)
Day’s Range― - ―
52-Week Range$2.80 - $4.83
Previous Close$3.86
Volume360.03K
Average Volume (3M)636.94K
Market Cap
$400.55M
Enterprise Value$458.70
Total Cash (Recent Filing)$207.97M
Total Debt (Recent Filing)$77.22M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Oct 29, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding99,146,740
10 Day Avg. Volume494,186
30 Day Avg. Volume636,936
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside163.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$9.60M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsStrong top-line growth and high gross margins indicate improving commercial traction and attractive product economics. If sustained, these trends could provide operating leverage as revenue scales, although the current base remains small.
Low Leverage And Asset SupportMinimal debt reduces interest and refinancing risk while the equity and asset base provide greater financial flexibility than a highly leveraged structure. This supports continued development, though ongoing losses could erode that cushion.
Approved Product And Late-Stage PipelineAn approved therapy provides commercial validation and a foundation for market expansion, while Phase 3 development offers a potential additional indication. Success could broaden the addressable rare-hematology opportunity and improve scale.
Bears Say
Large Ongoing Net LossesLosses remain exceptionally large relative to revenue, showing that operating expenses substantially exceed the current commercial base. Sustained deficits may delay self-funding, require additional capital, and limit the durability of reported growth.
Severe Cash BurnHeavy operating and free-cash-flow consumption indicates that development and commercial activities are not yet funded by internally generated cash. Unless revenue scales or costs decline, dependence on external funding remains a material structural risk.
Limited Recurring Revenue BaseThe business model still relies primarily on regulatory execution, commercialization, and external financing rather than an established recurring revenue stream. This increases exposure to approval outcomes, launch execution, and capital availability over the next several months.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $2.80 and its highest was $4.83 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
X4 Pharmaceuticals Inc’s market cap is $400.55M.
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.046.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is -0.18.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 99,146,740 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went up 11.271%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (163.79% Upside)
$11.00 (163.79% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $356.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$11.00
▲(163.79% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
15.34% Mutual Funds
61.38% Other Institutional Investors
14.78% Public Companies and
Individual Investors